Skip to main content

Crescent Biopharma, Inc Investor Event Transcript, Nov 10, 2026

Crescent Biopharma, Inc. (CBIO)

Crescent Bio plans Q1-2027 safety and tolerability data from 125-plus CR001 monotherapy patients, plus ORR results for up to 12 frontline non-small cell lung cancer patients against a 50 percent benchmark. AI summary

Investor Event Transcript 2026-11-10 For: 2026-12-31
Added on November 15, 2026

Conference Transcript - CBIO 2026-11-10

Stephen Willey, Analyst — Stiefel

We're going to go ahead and get started. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stiefel. Very glad to have with us for the afternoon session to kick things off. Crescent Bio, we have Josh Brown, the CEO. We have Ellie M., who is the Chief Medical Officer, and we have Jonathan B.B.O., who is the Chief Operating Officer. Thanks for joining us, guys. Any opening statements you guys want to make before we hop into Q&A?

Josh Brown, CEO

Yeah, just first of all, thanks for the invite. It's great to be here. We're going to kick off a really busy time for us coming into 2027. We'll be making some forward-looking statements today, so please refer to our SEC filings for those matters. But, look, you know, we've been now at the company since March 2025, Jonathan, Amy, and I, and Ellie, and really have been, if you look back where we were a year ago, just getting underway, signing to the Kloon agreement, and thinking about, you know, delivering on our strategy of combination therapy and where we thought the puck was moving in oncology. I think clearly that's been right. You've seen a lot of movement towards combos and thinking about the next-gen IO backbone with the class of bispecifics. I think there were kind of really three big questions that we had to answer when we came to this opportunity. One was, how are we going to compete with all the bispecifics coming out of China? Was the bispecific really a class of drug? And how would we catch up with those that were in front of us? And I think, you know, with the press list we put out a couple weeks ago, running into 2027 with a number of key data readouts and thinking about hitting middle of next year with over 2,000 patients dosed across our portfolio, we really haven't answered a lot of those questions. I think coming out of ASCO and the Harmony 6 data, pharma has shifted substantially from kind of being on the fence around the class of bi-specifics to pretty much everyone's now all in. We felt that and are excited about that validation for the class. I think we've, you know, clearly put ourselves as up next in the class with bi-specifics. You know, no one's going to really be able to come and catch us out of China. We're within 12 months of Phase III study starts now. We've said that early 28. And I think that we're just very excited about the execution the team's put in place. So a big year ahead of us, and we're going to rely on execution driving towards meaningful clinical data that I think will create value for our patients and our shareholders.

Stephen Willey, Analyst — Stiefel

All right. So I know you just provided a very kind of comprehensive update a couple of weeks ago, just with respect to kind of where you are and, you know, what investors should expect to see over the course of the next year or so. Maybe, I know you talked about the spaces going towards combinations, but maybe we can just first start with the monotherapy disclosure from the ASCEND trial next quarter. And it sounds like you're going to be prioritizing, you know, some efficacy data from, I think, up to 12 patients frontline long. This will presumably be some kind of, you know, benchmarking mechanism versus the competitor data that we've seen this far. How should we just think about the diversity of the patient population we're going to see here with respect to histology, CPS score? And is there a minimum duration of follow-up that you're hoping to have at the time that you disclose this data?

Josh Brown, CEO

Yeah, Elle, you want to talk about Q1 data and the data that's coming?

Ellie, Other

Sure. So happy to do that. In our global phase 1-2 study called ASCEND, we have started dosing patients in February of this year, And then we are enrolling patients from the United States, Europe, and South Korea. So we have released a press release on our progress a couple of weeks ago that we have dosed more than 125 patients of monotherapy CR001 in the study. And so we have completed dose escalation, and then tumor-type-specific vector cohort enrollment is ongoing. So with regards to the data package that we are working on to release in Q1-2027, includes safety tolerability coming from 125-plus patients of various tumor types and per-dose level. So that includes non-small cell lung cancer. And then we have four indications in the GI, including colorectal, gastric, HCC, and biliary. And then endometrial and cervical and ovarian as a guide to indications. So we'll get to share the safety and tolerability from various tumor types of the patients. Coming with PK data, which is also critical because we purposefully built this compound to match the key features of Ibanezmat. And then the pharmacodynamics data coming from Ibanez MEP phase 1 to study, looking at the PD-1 angle, PD-1 receptor occupancy data, as well as the VEGF angle, VEGF serum neutralization data. In terms of anti-tumor activity that you were alluding to, we will be focusing on up to 12 patients of frontline non-small cell lung cancer patients. It's because that's the setting that we have most amount of data validating anti-tumor activity of PD-1 VEGF, and it's also the cleanest way for us to compare our anti-tumor activity to ivenosumab as well as other leading PD-1 VEGF inhibitors. The TPS score that we have used to enroll non-small-cell lung cancer patients, looking at the HARMONY-2 study, regardless of TPS score of high versus low, most of all patients show the superior efficacy compared to pembrolizumab. And so we will be including patients TPS1 or higher percent to match that of Harmony2. And in terms of key efficacy data endpoint perspective, we will focus on ORR at this time. And so our benchmark will be 50 percent, again, coming from Harmony2 study. Oh, cool. Since we have started dosing patients in February of this year with the dose escalation, and then completing dose escalation in the summertime, and then going into the therapeutically relevant dose for the bacterial patients, this time around the follow-up for duration of response is relatively short. So that information will be shared at a later time once we have more data coming from the ASCEND study.

Stephen Willey, Analyst — Stiefel

Okay. Maybe you could talk a little bit about the decision to generate so much single agent data across all these different pre-specified tumor types. I know, you know, you need things like PK, PD. Safety to inform, you know, dose optimization and selection, but you're obviously not prioritizing any kind of efficacy data from this single agent kind of multi-tumor type cohort endeavor that you're pursuing. Thank you. I guess ultimately you still need to do a little bit of dose optimization work as you move into the chemo combos, right? So why 125 patients worth of monotherapy data?

Ellie, Other

I think that's a really good question. So we have intentionally designed a compound to match the key features of IVANESMEP, and then we started this global study to rapidly generate the safety tolerability as well as efficacy data of CR001. For us, a safety aspect was as important as the efficacy because since this compound or this class of the compounds will be used as a backbone of a combination with the various agents, so now we are carefully looking at the grade 3 or higher grade adverse events, immune-mediated adverse events were VEGF-mediated toxicities as well. So having pretty comprehensive safety and tolerability data from our monotherapy back to the cohort, followed by, again, going into the chemotherapy in our expansion cohort, and also, last but not least, coming from Cologne, SEC TMT, the Trope 280C. Plus O1 data. So in totality, then we'll have a comprehensive safety and tolerability as a monotherapy, chemo combo, as well as a topo ADC by middle of next year. So this was quite important for us to include all of those data sets.

Josh Brown, CEO

Yeah, I think it's a very intentional strategy to generate as much meaningful clinical data as we can across those three buckets. Our goal was to position our O1 asset as the best-in-class partner of choice, next-gen backbone IO therapy by middle 27 across those three buckets. I think when we started the partnership, it's been an incredible venue for us to create that data, and I would say it's just getting started. I think we as a company have been open for business. We understand the power of collaboration. We understand the power of combining across companies, across modalities to deliver for patients, and it's something that's important to who we are. So thinking about the data we're generating from the Kloon partnership and thinking about the multiple ADCs, I mean, I think they're giving Pharma a blueprint of how to think about taking the next-gen IO backbone, and I think soon enough you'll see them run that across their entire ADC portfolio. All of that data, all of the standard care chemo combo data, all the different chemo agents, and then also the monotherapy across the safety and efficacy will allow us to make sure that we have positioned this asset as a true backbone therapy. And I think that's the value. The space is so large, I talked about the three things we had to answer when we started, and one was like, how do you catch up? Well, I think we're now one of the leaders, right? And all of this data is what will put us there, and six months away is not that far. And then you think about leveraging them to phase three studies. Those phase three studies are a shot for us on goal at revenue for each phase three study we start. And the more data we have, the more we can invite others to come potentially work with us. We can think about royalty financing, having that data support some of those ideas so that we can go more broadly and pick off those best-in-class, first-in-class, fast-follower opportunities on that initial label transfer from first-gen PD-1 to second-gen. And we think on that foundational revenue of our first phase three study starts, we can do between $2 and $10 billion of revenue from those first phase three studies. Just to put that in context, Gilead is a top 10 oncology franchise, and that's $3 billion of revenue. So if you think about our opportunity to do between $2 and $10 billion of revenue from the first phase three studies we start, that puts us in the top 10 for quality of oncology franchises globally. And that doesn't even include the opportunity that we have when we get into the combinations for best-in-class with the ADCs or other modalities that we may combine with other ones. So this has been all intentional to lay the foundation with data to achieve our goal of that foundational revenue to replace the current labels of PD-1 with the next-gen IO backbone and win and best-in-class with the ADC combo therapies that we're working to bring together across the portfolio.

Stephen Willey, Analyst — Stiefel

Okay. Maybe you can talk a little bit about how comfortable you are relying on externally generated data, you know, from competitors, I guess, single agent or otherwise, to drive some of the clinical decision making. Oh, Charlie, you want to take that one?

Jonathan, COO

Yeah, I mean, what I'd say is that it depends on what external data it is, right? So, you know, we've rationally designed our molecule to replicate the cooperative pharmacology and safety profile of ibanesimab. So there's certain data that, you know, would inform us more than other molecules. But taking a step back, this is why we're generating all the data that Ellie and Josh just talked through, is that the external data will inform us. For example, we are very encouraged by the biliary tract data that was recently presented at ESMO by KESO and ibanesimab. But we will have our own data set across monotherapy, standard care chemo combos, and ADC combos that will be the primary driver of our decision set. We often get asked this week around the Pfizer SV data. Again, it's an interesting data set from an inter-bata-6 ADC perspective. But given that our own ADC, CRO3, is differentiated on antibody linker and payload, we can learn some things but not overly indexed on that external data set. So I think it is an input to our decision making, but it's not a core driver because of the robustness of our own internal data we're generating.

Stephen Willey, Analyst — Stiefel

I'll probably ask some of those same questions you've been asking about SV at some point. You talked about the chemo combo cohorts. I think there's seven of them, five different tumor types. Are you evaluating just a single 001 dose in those chemo combo cohorts and then choosing to do the dose optimization once you've decided on the combination and the tumor type specifically? How is that? Work logistically.

Ellie, Other

Yeah, it's a great question. So we are carefully studying our competitors registration enabling trials and what types of Data they need to generate to answer the recommended phase three dose question. And so based on that information, our goal is to generate comprehensive data as part of a SEND. And so that will allow us to go into the registration enabling studies in a more efficient fashion. So we have not shared a detailed plan on how we are addressing that part, and that's for competitive landscape issues. But we are focusing on generating comprehensive data as part of us in this study, and then going into the FDA meeting with the position of strength.

Josh Brown, CEO

Yeah, I think one way to think about it is we won't need to do a dose escalation part of our Phase III study. We'll have that work done before we start our base three studies.

Stephen Willey, Analyst — Stiefel

Okay. How are you strategically thinking about the disclosure of the chemo combo data? I know you've mentioned this should start to reveal itself at some point in the middle part of next year, but how do you think about it in terms of the amount of patient data that you wanted to be able to disclose from each cohort, and maybe more importantly, just the cadence of cohort-specific disclosures? Do you see? You know, kind of a staggering of these coming out of various relevant medical conferences throughout the back half of the year.

Josh Brown, CEO

Yeah, I'd say stay tuned on that. We haven't got into that level of granularity yet, but what we have said is, you know, ORRs will be a part of that. It's 20 to 40 patients per cohort, so it's a robust cohort of patient data. If you look across some of the other data that's out there from phase two studies, you know, 22, 26, 30 patients worth of data. So it's a robust data set. ORR will be a part of that. Obviously, safety tolerability, PK, All the things that really you'd want to see out of that data disclosure. We may or may not disclose all the cohorts worth of data. We may focus on a few, and we may focus on the ones where we potentially think about going forward in Phase III studies. And as I mentioned in previous talks, you know, we may pick a Phase III indication that's not part of the standard care QMO combo indications today. So we're still looking at some of those opportunities. But I'd say more to come on that as we get closer to the middle next year.

Stephen Willey, Analyst — Stiefel

And then how do you think about the ROI associated with? Pursuing these registrational chemo combo trials where, you know, there's competitor chemo combo data for a lot of the tumor types that you're pursuing here versus the ROI of potentially, you know, having a first mover advantage on some of the registrational combos that you can pursue with ADCs.

Josh Brown, CEO

Yeah. Jonathan, you want to take that?

Jonathan, COO

Yeah, I mean, look, the competitive data, our own data, and classic market analysis, including ROI, all three of those factors will go into our decision making around which phase three studies to prioritize. So it's certainly on our mind. That being said, other than if you look at the standard care chemo combos, yes, there are phase threes initiated on small cell. There's some phase three initiated in colorectal. We will not be first there with those chemo combos. That being said, those are larger markets. That being third or fourth could be meaningful, even potentially blockbuster opportunities. For some of the other chemo combos, standard care chemo combos we could pursue, we could be one of the first, if not the first, outside of China to pursue those. So all of those factors of being potentially first in class or being a fast follower come into that. And then the ADC combo strategy is, of course, core to our strategies. We think about synergistic combination. The question of when you start those trials depends on the stage of the ADC that you're combining with. Is it an approved or late-stage ADC or is it earlier? But one can imagine for some of these markets, it may make sense even to take multiple shots on goals, such as Lung, where you can do a chemo combo and potentially an ADC combo. So it is a factor in our decision-making, and there's an opportunity to be first in class and best in class. And honestly, this just speaks to the breadth and scope with this $100 billion-plus market opportunity.

Josh Brown, CEO

Yeah, maybe I'll just add to something that Ellie is constantly talking about around the building is that it matters where you finish, not where you start. And so I think that's something that people should remember. Because, you know, her own experience with Jen Perley, Tessaro, and Demetrio winning first line, you know, for the seventh PD-1 approved in the first generation of that movie. I think it's also, you know, important for people to go back and look at history. You know, we've had the first movie of the PD-1 world, you know, you had, you know, a fight to who ultimately won that with Keytrude and Optivo. Optivo was in the lead. Keytrude came back into $30 billion of that revenue. You know, 9, 10, PD-1s approved. But the reminder of that is not all those phase three studies were successful, right? So strategy matters, trial design matters, execution matters, and it's not always where you start, but it's where you finish. And so we'd like an indication that maybe we could have a chance to be first in, but maybe we start right behind somebody. We still have an opportunity to be first mover there. And again, in that first generation of foundational revenue of our first study starts at Phase III, $2 to $10 billion of revenue is massive for a biotech. And so it's not lost sight on us. It doesn't mean that we would prioritize that over the full matrix portfolio that we have. And we are very fortunate to have today three clinical programs in the clinic dosing patients, and we're actively looking for other things to combine with O01. And so we're going to be very aggressive about that. As I said earlier, we're open for business. We're talking to people all the time about how we can advance combinations for patients, and those two will become facer opportunities for us. So we have to prioritize all that. Some will be driven by capital. Some will be driven by partnering. But we're very excited about the data we're generating and the foundation we're building for the initial revenue.

Stephen Willey, Analyst — Stiefel

So I know you and your partner, Kouloun, are kind of in the process of laying all that groundwork now for the ADC-based combos. Would you expect that development effort to look, I guess, a SEND-like in the sense that you're kind of interrogating this broad spectrum of tumor types? Or would you expect those decisions in terms of where to go to be made kind of a lot more surgically? Ali, Jonathan, thoughts?

Jonathan, COO

We will start with, like, what's going on right now, and then we can go to where we could go. So right now, Colun has currently initiated three phase two studies of SAC TMT plus O1 in China. Those span different forms of non-small cell lung cancer and multiple other advanced solid tumor types. So there it's reflecting the data today they've seen of where SAC TMT has activity. For additional ADCs, we could pursue either independently or in collaboration with Colun. You can imagine an additional, a similar approach, which is that you want to select indications where that ADC you believe has the opportunity to improve upon the standard of care. So it may be non-small cell lung cancer, it may be head and neck cancer in the context of integral beta 6. For PD-L1, which is our other internally developed ADC, it may be similar or other additional indications. So, it will depend upon the ADC target, but I think the common commitment is you're looking at the combination therapy, and then where do you think that you can make a difference for patients, both later-line patients, but particularly earlier-line patients, where we think there's significant market opportunities in many of these indications.

Ellie, Other

Can you do that, Ellie? Yeah, yeah, since our PD-L1 ADC, which is just the, we are initiating a first in human trial, which is a global study, and then the Inogen Beta 6 ADC, which our partner Colun is. Running phase 1, 2 study, for us to find the recommended phase 2 dose and then the indications that we want to expand upon, it takes a little bit of time for us to get there. So I think that's where we have a unique advantage of working with the cologne, where they have multiple ADCs that are already either approved or in the late stage development. So start generating the data of a PD-1 VEGF plus leading ADCs of a topop payload, it gives us a sense of what can be that synergistic effect, and then going into the potentially best-in-class profile of various indications. Because our ADCs are in early stage development, the fact that we can start generating this data in indications where Colun already has shared their monotherapy activity, where sometimes with a sec TMT, in combination with PD-1 inhibitor, so we can see the delta of efficacy that are generated because it's combined with a PD-1 VEGF. And also looking at the safety profile, that it is well tolerated, and then it can be used in earlier lines of setting. All these informations are critical for us to, A, demonstrate the safety and tolerability profile and efficacy profile of all one, and also in terms of making our own decisions on which indications to choose and then where to pivot. Okay.

Stephen Willey, Analyst — Stiefel

And I think you guys are guiding to some initial data from that Colune sponsored trial of 001 and SAC TMT and lung sometime in the middle part of next year? I'm sure there will be a lot of interest in that, given that I think. Yeah, there's, you know, over 852,000 patients coming from those three studies. Well, it was the one obvious question that everyone who was sitting through the Optotrap 1-06 trial at asthma was asking themselves, right?

Jonathan, COO

Yeah, yeah. So we'll get the first early answer there.

Stephen Willey, Analyst — Stiefel

The collaboration with Colune, I know we talked about the Pfizer version of the integrin beta 6 and, you know, perhaps why the read through there is not so. It's not so translatable in terms of what you were doing, right, in terms of having a novel scaffold, a novel anchor, a novel payload, but just curious, you know, we saw the data at ESMO, I think, obviously, pretty underwhelming. How are you thinking about integrating beta 6 now just as a target? And, you know, if that Pfizer data. If there's anything about it at all that kind of changes your perspective on the validity of integrin-beta-6 as a target.

Ellie, Other

Yeah. To start with our conviction and focus on inner green beta 6 ADC-03, it hasn't changed it, and it's because we believe in the target. It's overexpressed in multiple tumor types that we are interested in, and it fits really well with our matrix portfolio going into lung, head and neck, and GI, as well as a gynonk indications. And its expression on normal tissue is relatively low. That's why we thought that inner green beta 6 itself is a really great target for an ADC. From Pfizer's Phase I study data, where they shared the safety and efficacy from non-small cell lung and head and neck cancer, we saw that there was encouraging anti-tumor activity, but then we also saw the limitations of that asset partially coming from MMA-related toxicity, such as neuropathy, hemtox. Going into the DLTs, as well as dose interruption and treatment discontinuation. And so when we worked with Colune and then picking this ADC for our pipeline, we really liked the fact that all three, you know, Green Beta 6 ADC of ours, is focusing on internalization from the antibody perspective. And also it's FC null. Anybody, which potentially can mitigate for risk of pneumonitis, which we know that SV data showed as one of the safety concerns of that asset, showing some patients with grade 5 events coming from lung toxicity. And also using more stable linker, we are anticipating wider therapeutic index. Again, another issue that we saw from SVE, where they had to change the dose regimen, as well as how they're dosing patients in the middle of phase three study. And I think it just inherently comes from how narrow therapeutic index of that asset is. And so going with the moderately potent topo payload of a DAO of eight with the excellent bystander effect, we thought that this is a really well-optimized version of the inner green beta 6 ADC. And that's why we are feeling pretty confident that now we're in a leading position, we can create differentiated efficacy and safety profile compared to Pfizer's.

Stephen Willey, Analyst — Stiefel

Okay. Yeah, I wanted to ask you, I guess, maybe specifically about the lung toxicity that's been seen with the Pfizer asset. You mentioned the five grade five events that we're seeing in the head-to-head trial versus docetaxel. I know they saw another, I think, five grade five AEs combining with Pembro in a pretty small patient cohort in frontline patients. And when you think about the talks and whether or not you think it might be. Scaffold-related, right? Whether it's epitope binding to integrin beta 6 or maybe FC or the payload itself. I know there's been some pneumonitis historically suggested with the Bedotin payloads, but just curious, as you think about the lung toxicity and maybe the causality of that, do you have any thoughts on it at all?

Ellie, Other

Yeah, it's a really great question. And any of the ADCs that are being developed in non-small cell lung cancer, I think the risk of pneumonitis is something that every ADC has to face. And so we noted that number as a monotherapy high-grade pneumonitis that was reported from SIGVED. And looking at various ADCs of TOPA payload or MMA payloads, we are seeing pneumonitis as a potential risk of these ADCs, especially developed in non-small cell lung cancer patients. Expression of erogin-beta-6 itself in normal lung epithelial cells is not necessarily high, right? So having said that, I don't think we know exactly how that number was target-mediated versus other things that are related from that SV cells. Yeah, such as the antibody with FC wild type, as I mentioned, that could increase the risk of pneumonitis. And then the linker, Valsit linker, which is not as stable, and then the potent MMA payload, all those things together, we think that could have increased the risk of pneumonitis and lung tox. So while we are noting that as a potential risk that SV shared, we are approaching our own clinical development with a very careful way so that, of course, patient safety comes first. But I don't think at this time there's any clear evidence to suggest that that is target mediated toxicity.

Stephen Willey, Analyst — Stiefel

And I guess Pfizer has a follow-on version that is topo-conjugated, but has the same exact antibody scaffold? So maybe I guess we'll get some clarity there. I mean, look, I know that you guys have done kind of a very good job, whether it's intentional or not, over the last 12 months of kind of creating some distance between yourself and Summit. But, you know, the stock, at least the way that it behaves, is still pretty materially tied to Summit. So, you know, I guess I have to kind of ask you, like, what's your level of confidence as we kind of go into this expected Harmony 3 disclosure?

Josh Brown, CEO

Yeah, look, I think it's a fair question for the time being. And I think we will have our day in the sun coming, starting in Q1 next year with our own data. But, you know, I think there's no reason for us to believe that we won't see a positive read through in the PFS. And I think they've even guided to OS being immature and thinking about that being more of a next year, you know, kind of endpoint for them. But, you know, look, I think we've been very fortunate in this, you know, sequel of the PD-1 space to have the first four studies read out positively, you know, within lung and now outside lung in the BTC space. And so I think there's a strong conviction, as I mentioned, even from pharma, from pre-ASCO to now, that this is a classic drug. I do think that the Harmony 3 readout is a specific issue that Summit has to work through. I do not think it's a read-through to the class. I think we will hopefully learn from the teachings from the Harmony 3 study and how they designed it and whatnot and can maybe make some of those changes as we think about our final study designs for our initial Phase 3s. But I think for us, you know, it would make it easier for the space, obviously, you know, from an investor perspective, if it's a successful readout. But it's not going to really change our core focus strategy on developing our O01 asset or how we think about, you know, our portfolio. So, obviously, wish them the best. And I think we'll have our day in the sun, as I said, when we start developing our own data and our own phase three studies. And just a reminder that historically, you know, all those initial PD-1 studies, not every phase three study read out positively. And I expect that'll be the case here, too, in the second-gen version of the movie.

Stephen Willey, Analyst — Stiefel

And then... Maybe lastly, how do you think about the potential advantages of being afforded the hindsight to actually kind of pivot? You just referenced this a little bit, to be able to pivot off some of the data and maybe even more importantly, some of the decisions that have been made by Summit. I know investors aren't really kind of giving you guys a first mover advantage premium, but it seemed to me that kind of being able to sit back and learn what not to do. From a development and execution perspective, it has some very underappreciated advantages as well.

Josh Brown, CEO

Yeah, I'll start, and let me ask Jonathan to pine here a bit. But the biggest thing for us is we're starting with the Western patient data, right? We don't have to answer this question out there. It's global data. There's not the Chinese piece of it. Now, marrying that to the Western data and then having to think about the timing of when you pull those poles or going through an interim look pre-ASCO and Harmony 3 did and kind of stubbed their toe a bit on that. I think they even talked about that. You know, they weren't quite ready for that when they did it and looking back on it, et cetera. So those are things that we can learn from, and we don't have to answer those questions because we're going to have that in the data right out of the gate. But I don't know, Jonathan, other things that you think are relevant here?

Jonathan, COO

I mean, one key one is they've done a wonderful job of demonstrating the monotherapy potential of the PD-1-BGF class, and specifically ibanesimab. But as we think about our own phase two registrational studies, you know, we will generate monotherapy data that we talked through in Ascend. But beyond that, we can jump ahead to SanityCare chemo combos, to ADC combos. So that is a benefit we have from being a fast follower in the space more broadly, but it allows us to lead in specific indication and specific revenue opportunities because of that. So I think that we get to learn from the data. We get to see where it's going. And frankly, it allows us to take calculated risks as we think about our Phase III studies as well, right? And we can learn from those. So I think it's a great place to be. And I think it also just, again, speaks to the size of the market, where no one is going to be a first-mover advantage on every solid tumor indication across the $100 billion-plus market. And that is where we have an opportunity to truly carve out meaningful opportunities for patients and for revenue in this master space that encompasses a lot of all of oncology.

Josh Brown, CEO

Yeah, and I would just say that, you know, this is the seventh company that I've been a part of building. And, you know, clinical strategy and execution and learning from trial design is important, and we absolutely are doing that. And a fast follower approach here is super beneficial. But, you know, you've got to win with quality across all functions of the business. Are you ready for manufacturing CMC? Are you ready for commercial? Are you ready for medical affairs? Do you have the ability to make those investments and the people on the team you put together? And I would just say that those things often also cause delays in programs. And so we are going to lead with quality and making sure that from a manufacturability standpoint, we're in a good spot. We've already shown that we can go to sub-Q, a sub-Q opportunity with high enough formulations. So things like that that we can compete and win on over time. In addition to the safety and efficacy of the drugs in our portfolio are going to matter. But you've got to make sure you tick and tie all the other boxes and all the functional inputs to launching a successful drug. All right. I think that's an appropriate ending point.

Stephen Willey, Analyst — Stiefel

So, guys, thank you very much. Thanks, everyone, for listening. Thank you. Appreciate it.